The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Phase II/III trial meets PFS primary endpoint in previously untreated metastatic or unresectable melanoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The phase II/III RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo (nivolumab) versus Opdivo alone in patients with previously untreated metastatic or unresectable melanoma met its primary endpoint of progression-free survival.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Capitol Hill

At House hearing, Democrats clash with RFK Jr. over “radical obstruction of congressional oversight,” vaccine policies
Rep. Lori Trahan: “People are going to die”

Secretary of the U.S. Department of Health and Human Services Robert F. Kennedy Jr. appeared before the House Energy and Commerce Subcommittee on Health to defend the HHS fiscal year 2026 budget proposal, and faced criticism from several Democratic lawmakers on what they described as a lack of transparency and scientific rigor in the agency’s recent decisions.
By Claire Marie Porter
Guest Editorial

Building cancer care resilience through international observerships: Lessons from Ukraine

The full-scale Russian invasion of Ukraine has devastated the Ukrainian healthcare infrastructure, disrupting cancer care, halting clinical trials, and compounding long-standing systemic challenges.  Even before the war, Ukraine’s oncology system faced major constraints: Limited access to radiotherapy equipment, outdated chemotherapy supply chains, and workforce shortages. The invasion intensified these issues—cancer hospitals were damaged, warehouses destroyed,...

By Nataliya Kovalchuk, Andriy Beznosenko, Vitaliy Y. Poylin, Rostyslav Semikov, Arman Kacharian, Douglas Davis, Nataliya Uboha, Natalka Suchowerska, Viktor Iakovenko, Jacqueline Hart, Mark Poznansky, Darya Kizub and Nelya Melnitchouk
ClinicalTrials & Tribulations

As cancer patients use AI chatbots, dangers lurk—but new safeguards can help

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers. 
By Ghulam Rasool, Brian D. Gonzalez and Katherine Chung-Bridges
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account